Open Trials

Funded Clinical Study for Dogs with Lymphoma

ACI is currently enrolling cases in a nationwide clinical trial to evaluate safety and efficacy of a novel PI3 Kinase Delta Inhibitor (RV1001) in dogs with naïve or first relapse lymphoma.


Trial Summary

An estimated 30 client-owned dogs will be enrolled in this study. Weekly visits will be required for the first 6 weeks of the study, at which point patients will continue with biweekly visits for 6 more weeks. Owners will administer the study compound orally in 5-days on, 2-days off cycles. The study duration is 3 months; however, if enrolled dogs are benefiting from treatment, they will have the option to continue on the study agent.

Trial Funding
This study is fully funded for the 3-month study period. At the Screening Visit dogs will have a physical exam, bloodwork (CBC and chemistry) and urinalysis, thoracic radiographs, and flow cytometry to determine if the patient has B-cell or T-cell lymphoma (both T-cell and B-cell cases may enroll).Once the dog is confirmed eligible (meets the inclusion and exclusion criteria outlined below), all procedures and treatments required by the study including study therapy, exam, bloodwork, and other required diagnostics will be fully funded.

Trial Eligibility
To qualify for enrollment, dogs must meet the following criteria:

  • Dog has been diagnosed with histologically or cytologically confirmed T or B cell lymphoma, either newly diagnosed or first relapse
  • Dog must be at least 1 year of age
  • Dog must have at least one peripherally located lymph node measuring ≥ 2 cm longest diameter
  • Dog must demonstrate adequate organ function as indicated by standard laboratory tests (complete blood count, serum biochemistry profile, urinalysis)
    • ANC ≥ 1000/μL and platelet count ≥ 80,000/μL
    • Liver: Total bilirubin ≤ 1.5X the institutional upper limit of normal (ULN), ALT ≤ 3X ULN
    • Renal: Serum creatinine ≤ 1.5X ULN
    • ECOG performance score of 0-1 [0 = normal activity; 1 = restricted activity: decreased activity from pre-disease status]
  • Dog must have an estimated life expectancy of at least 28 days
  • Any prior chemotherapy or radiation must be completed 7 days prior to study entry and the patient must have recovered from any acute toxicities of treatment(s)
  • The owner must be able to orally administer drug according to designated schedule

Dogs cannot be enrolled if any of the following conditions are met:

  • Dog has evidence of central nervous system involvement
  • Dog has uncontrolled autoimmune hemolytic anemia (AIHA) or immune mediated thrombocytopenia (ITP)
  • Concurrent use of complementary or alternative medicines that in the opinion of the investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug
  • Dog has significant cardiovascular disease
  • Dog underwent a major surgical procedure less than 14 days before screening
  • Dog has any serious systemic disorder incompatible with the study (at the discretion of the oncologist)
  • Dog has been administered any other investigational drug within 7 days of study entry
  • Dog is pregnant or lactating

Trial Participation

The following veterinary oncology centers are offering this clinical trial:

The Ohio State University
Veterinary Medical Center

601 Vernon L Tharp St.
Columbus, OH 43210
(614) 247-8706

Las Vegas Veterinary Specialty Center
8650 W. Tropicana Ave
Suite B-107
Las Vegas, NV 89147
(702) 871-1152

BluePearl Veterinary Partners – Overland Park
11950 West 110th St
Overland Park, KS 66210
(913) 642-9563

New England Veterinary Oncology Group
180 Bear Hill Rd. Suite C
Waltham, MA 02451
(781) 684-8688

A Pilot Multicenter Field Study of a Novel Oral Therapeutic in Dogs with Canine Atopic Dermatitis

ACI is currently enrolling cases in a nationwide clinical trial to evaluate novel therapeutic designed to inhibit inflammation in dogs with atopic dermatitis. The study is designed to assess the benefit after a course of prednisone or independently.


Trial Summary

An estimated 75 client-owned dogs will be enrolled in this study. At enrollment, dogs will be randomized 4:1 prednisone to study drug. Those dogs randomized to receive prednisone will then be randomized again at Day 14 if pruritus and skin lesions caused by atopy have improved adequately. The veterinary dermatologist, and dog owner, will be masked to treatment group assignment. Study visits are required every 2 weeks for one month, and then monthly thereafter. The study duration is 4 months; however, if the dog does not respond to prednisone treatment or experiences a flare of atopic dermatitis after enrollment, the dog may be removed from study.

Trial Funding

Dogs presenting to the participating trial site will be screened for enrollment. All study related costs, including screening, are paid by the study. Either IgE serology (through IDEXX) or intradermal skin testing will be needed if not previously performed. Although previous studies with this drug have not demonstrated significant side effects , the study will pay up to $250 for medical management of adverse effects if they are thought to be a result of the study drug. If these funds are not used in full during the course of the study, the balance will be available to study pet owners for follow-up dermatology care.

Trial Eligibility

To qualify for enrollment, dogs must meet the following criteria:

  • Client-owned dog > 1 year of age
  • Body weight ≥ 5.0 kg
  • Diagnosis of Atopic Dermatitis based on clinical signs, rule-out of resembling conditions (e.g. flea allergies, ectoparasites and bacterial or yeast skin infections). For homogeneity purposes, dogs with food-induced AD will be eliminated from inclusion.
  • Non-seasonal Atopic Dermatitis
  • More than 3 positives on allergen-specific IgE serology or intradermal testing
  • Canine Atopic Dermatitis Extent and Severity Index-4 (CADESI-4) Score of ≥ 25
  • Pruritus Score ≥ 5.5
  • Use of a veterinarian recommended flea product, in endemic areas, for a minimum of 3 months.

Dogs cannot be enrolled if there has been:

  • Use of the following medications from the time of enrollment:
    1. Injectable long-acting glucocorticoids in the past 6 weeks
    2. Oral glucocorticoids, cyclosporine, calcineurin inhibitors, long-acting injectable antimicrobial agents or agents with known anti-pruritic activity (Staphage Lysate, gabapentin, monoamine oxidase inhibitors and tacrolimus) in the past 4 weeks
    3. Topical nonsteroidal anti-inflammatory drugs and topical glucocorticoids in the past 3 weeks
    4. Anti-histamines and oclacitinib in the past two weeks
    5. Oral antibacterial or antifungal agents in the past week.
  • Use of allergen-specific immunotherapy initiated in the last year (If allergen-specific immunotherapy has been used for more than 1 year, dog is still eligible)
  • History of seasonal Atopic Dermatitis
  • Evidence of ectoparasites or bacterial or yeast infection
  • Change of food or food supplements (fatty acids, omega-3s) within the last 6 weeks
  • Dog is pregnant, likely to become pregnant or intended for breeding
  • Dog has another major medical condition requiring pharmaceutical intervention
  • Dog has a serum chemistry, hematology or UA finding that is, in the opinion of the Investigator, clinically significant and may indicate a concomitant illness.
  • Dog is participating in another study
  • Dog may not be available for the entire study duration
  • Owners unable or unwilling to assess pruritus throughout the study

Trial Participation

The following veterinary dermatology centers are offering this clinical trial:

Animal Dermatology Clinic
2965 Edinger Ave
Tustin, CA 92780
(949) 936-0066
Animal Dermatology Clinic
5610 Kearny Mesa Rd, #B1
San Diego, CA 92111
(858) 560-9393
Dermatology for Animals
86 West Juniper Ave
Gilbert, AZ 85233
(480) 633-2277
Dermatology for Animals
106 East Campbell Ave
Campbell, CA 95008
(408) 871-3800
Animal Allergy and Dermatology
1100 Eden Way North
Chesapeake, VA 23320
(757) 366-9000
Veterinary Emergency & Specialty Center of New Mexico
4000 Montgomery Blvd NE
Albuquerque, NM 87109
(505) 881-7205

Great Pyrenees with Osteosarcoma

ACI is conducting a study that collects saliva sample, buccal (cheek) swabs, and a small amount of whole blood from Great Pyrenees that are diagnosed with Osteosarcoma. Eligible dogs may be newly diagnosed, currently receiving therapy, or previously treated.

Trial Eligibility:

  • Any purebred Great Pyrenees with Osteosarcoma
  • Any age, breed, or sex is eligible

Trial Support

This study is a voluntary study for pet owners whose dogs meet the above criteria.

Saliva collection kits and buccal swabs will be provided to pet owners at no charge with sampling and mailing instructions inside. A kit with prepaid return packaging will be mailed to the owners for quick and easy return. Blood samples are requested, but not mandatory. Please contact ACI for information on how a blood samples can be obtained in your area.